Aktis Oncology, Inc. (AKTS) vs Galecto, Inc. (DMRA)
Aktis Oncology, Inc. and Galecto, Inc. are both Biotechnology companies. Galecto, Inc. is the larger, with a market value of $1.3B against $1.1B — 1.1× the size. Galecto, Inc. has the higher net margin (0.00% vs −782.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Galecto, Inc. leads on 8 and Aktis Oncology, Inc. on 4.
Valuation
Profitability
| Metric | AKTS | DMRA | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 0.00% | 65.16% |
| Operating margin | (939.13%) | 0.00% | 0.00% |
| Net margin | (781.95%) | 0.00% | 0.00% |
| Free cash flow margin | (1,442.91%) | 0.00% | 0.00% |
| Return on equity | (34.45%) | (26.26%) | (57.72%) |
| Return on assets | (27.09%) | (18.64%) | (49.22%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack